An article about NAD+ may cite a trial of nicotinamide riboside. A supplement label may feature nicotinamide mononucleotide. The names are connected through metabolism, but the products and experiments are not identical.
Keeping the abbreviations straight is more than a vocabulary exercise. It helps prevent evidence from one ingredient or route from being quietly used to sell another.
THE USEFUL DISTINCTION
Match the exact ingredient and route in a claim to the ingredient and route in the cited study.
NAD+ is the coenzyme in the discussion
NAD participates in cellular reactions, including those involved in energy metabolism. Its importance is a statement about biology. An oral capsule, a nasal product, and a compounded injection marketed around that biology each need their own product-specific evaluation.
The NAD introduction starts with that distinction. The fact that the body uses a molecule does not tell you which commercial intervention, if any, would produce a worthwhile clinical benefit for you.
Evidence: NIH ODS: niacin and NAD metabolism / FDA: compounding and approval
NR is a precursor studied on its own
Nicotinamide riboside is an NAD precursor. Human trials of oral NR have investigated NAD-related biomarkers and, in some populations, clinical measures. The 2018 crossover study in healthy middle-aged and older adults was small and short, with exploratory physiological findings.
A separate peripheral artery disease trial addressed walking performance in people with that condition. Its population and outcome matter. Neither study establishes that a different preparation, such as a subcutaneous NAD+ injection, has the same effects.
Evidence: Martens et al.: 2018 oral NR crossover trial / McDermott et al.: 2024 NICE trial
NMN has a separate research record
Nicotinamide mononucleotide is another intermediate in NAD biosynthesis. A 2021 randomized trial examined metabolic effects of NMN in postmenopausal women with prediabetes who were overweight or obese. That is a defined population and intervention, not a demonstration of universal anti-aging effects.
Do not combine every positive result from NR and NMN research into an imagined single body of proof for any product labeled NAD support. The study explorer demonstrates a method for preserving those boundaries.
Evidence: Yoshino et al.: 2021 NMN metabolic trial
Combinations add another distinction
Elysium Basis combines NR with pterostilbene. Its published trial concerns that combination under the study conditions. Our Basis review explains why it belongs in a separate supplement category rather than being ranked as an injectable provider.
If your question is about an injection or infusion, read the route comparison and sterile-compounding safety note. Route-specific risks and clinical evidence are not resolved by choosing the abbreviation that sounds most familiar.
Evidence: Dellinger et al.: 2017 NRPT randomized trial / Elysium: Basis product and subscription terms / FDA: suitable ingredients for sterile compounding
Open the source material
- NIH ODS: niacin and NAD metabolism
Nutritional and biochemical background, not evidence that a commercial NAD intervention improves longevity.
- FDA: compounding and approval
Compounded drugs are not FDA-approved; ingredient evidence does not certify the finished preparation.
- Martens et al.: 2018 oral NR crossover trial
Small, short-duration human study of oral NR; cannot establish effectiveness of injectable NAD+.
- McDermott et al.: 2024 NICE trial
Randomized trial in peripheral artery disease. A condition-specific oral NR result is not general proof for all NAD products.
- Yoshino et al.: 2021 NMN metabolic trial
Ten-week randomized trial in postmenopausal women with prediabetes; findings remain specific to the intervention and population.
- Dellinger et al.: 2017 NRPT randomized trial
120 adults aged 60–80, eight weeks; NAD+ biomarker and safety outcomes. Elysium funded the study; not evidence of longer life.
- Elysium: Basis product and subscription terms
Oral NR plus pterostilbene supplement, not injectable NAD+. Marketing and purchase terms are separate from clinical trial results.
- FDA: suitable ingredients for sterile compounding
Specific NAD+ safety communication: food-grade material, contamination risk and reported adverse events.
